Evaluating the Safety of Bristol Myers Squibb’s Dividend Yield

Key Points

• Bristol Myers Squibb offers a dividend yield that exceeds the average for pharmaceutical companies, while facing upcoming patent expirations.

• The payout ratio remains reasonable, and the company maintains a solid financial position despite typical pharmaceutical sector challenges.

Bristol Myers Squibb (NYSE: BMY) currently delivers a 4.5% dividend yield, significantly higher than the 1% yield of the S&P 500 index and the sector average of 1.6%. Although this yield appears attractive, investors should assess the dividend’s safety. The outlook suggests a strong likelihood of continued payments.

Bristol Myers Squibb is a well-run business

Bristol Myers Squibb is an established, long‑standing pharmaceutical company with a respected track record. While its dividend has not risen annually, it has generally trended upward over many decades, reflecting the firm’s operational strength and the board’s commitment to shareholder returns.

Ultimately, the board of directors determines Bristol Myers Squibb’s dividend policy. Investors should examine key metrics to gauge the safety of its elevated yield. The payout ratio stands at approximately 72%, which, while relatively high, remains within acceptable limits and provides some cushion before a potential reduction would be required.

Image source: Getty Images.

There are reasons to worry about Bristol Myers Squibb’s dividend

However, several key products—Revlimid, Pomalyst, and the Pfizer‑co‑marketed Eliquis—are facing patent expiration, which could pressure both revenue and earnings in the coming years. Although the company is pursuing new product development to offset this loss, the typical lag between patent expiry and the launch of replacements is a common challenge in the industry, potentially causing the payout ratio to increase short‑term.

Consequently, a review of the balance sheet is warranted. Bristol Myers Squibb holds an investment‑grade credit rating and demonstrates financial strength, with a debt‑to‑equity ratio of 2.2x—down from 3.0x at the end of 2024—and an interest coverage ratio of 6.3x, indicating comfortable capacity to service debt. These metrics suggest the firm could absorb additional borrowing if necessary to sustain its operations and dividend.

Not for super conservative investors, but not a huge risk either

Investors who cannot tolerate significant uncertainty may find the 4.5% yield unsuitable for their dividend portfolio. Nonetheless, the company’s lengthy record of success, a payout ratio that is high yet manageable, and a robust financial profile together offer reasonable confidence that the dividend can endure the current patent‑expiration pressures.

Consideration for Potential Investors

Prospective investors should weigh the attractive dividend yield against the near‑term challenges posed by upcoming patent expirations and their impact on earnings. Given the company’s solid financial footing, the dividend appears reasonably secure for investors comfortable with moderate risk.

Source link